276 related articles for article (PubMed ID: 1359174)
1. Prognostic factors for recurrent breast cancer: univariate and multivariate analyses including histologic grade and amplification of the c-erbB-2 proto-oncogene.
Tsuda H; Tsugane S; Fukutomi T; Nanasawa T; Yamamoto H; Hirohashi S
Jpn J Clin Oncol; 1992 Aug; 22(4):244-9. PubMed ID: 1359174
[TBL] [Abstract][Full Text] [Related]
2. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
4. Int-2/FGF3 amplification is a better independent predictor of relapse than c-myc and c-erbB-2/neu amplifications in primary human breast cancer.
Champème MH; Bièche I; Hacène K; Lidereau R
Mod Pathol; 1994 Dec; 7(9):900-5. PubMed ID: 7892157
[TBL] [Abstract][Full Text] [Related]
5. Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1.
Tsuda H; Hirohashi S; Shimosato Y; Hirota T; Tsugane S; Yamamoto H; Miyajima N; Toyoshima K; Yamamoto T; Yokota J
Cancer Res; 1989 Jun; 49(11):3104-8. PubMed ID: 2566377
[TBL] [Abstract][Full Text] [Related]
6. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.
Berns EM; Klijn JG; van Putten WL; van Staveren IL; Portengen H; Foekens JA
Cancer Res; 1992 Mar; 52(5):1107-13. PubMed ID: 1737370
[TBL] [Abstract][Full Text] [Related]
7. ERBB2 amplification in breast cancer with a high rate of proliferation.
Borg A; Baldetorp B; Fernö M; Killander D; Olsson H; Sigurdsson H
Oncogene; 1991 Jan; 6(1):137-43. PubMed ID: 1671531
[TBL] [Abstract][Full Text] [Related]
8. [Preliminary studies on c-erbB-2 protooncogene in breast cancer].
He LW
Zhonghua Zhong Liu Za Zhi; 1992 May; 14(3):171-4. PubMed ID: 1356719
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer.
Giai M; Roagna R; Ponzone R; De Bortoli M; Dati C; Sismondi P
Anticancer Res; 1994; 14(3B):1441-50. PubMed ID: 7915096
[TBL] [Abstract][Full Text] [Related]
10. c-erbB-2 oncogene related to p53 expression, cell proliferation and prognosis in breast cancer.
Lipponen HJ; Aaltomaa S; Syrjänen S; Syrjänen K
Anticancer Res; 1993; 13(4):1147-52. PubMed ID: 8102517
[TBL] [Abstract][Full Text] [Related]
11. Proto-oncogene amplification and human breast tumor phenotype.
Adnane J; Gaudray P; Simon MP; Simony-Lafontaine J; Jeanteur P; Theillet C
Oncogene; 1989 Nov; 4(11):1389-95. PubMed ID: 2554239
[TBL] [Abstract][Full Text] [Related]
12. Determination of c-myc amplification and overexpression in breast cancer patients: evaluation of its prognostic value against c-erbB-2, cathepsin-D and clinicopathological characteristics using univariate and multivariate analysis.
Scorilas A; Trangas T; Yotis J; Pateras C; Talieri M
Br J Cancer; 1999 Dec; 81(8):1385-91. PubMed ID: 10604737
[TBL] [Abstract][Full Text] [Related]
13. Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer.
Le Roy X; Escot C; Brouillet JP; Theillet C; Maudelonde T; Simony-Lafontaine J; Pujol H; Rochefort H
Oncogene; 1991 Mar; 6(3):431-7. PubMed ID: 1707153
[TBL] [Abstract][Full Text] [Related]
14. Multivariate analysis of bcl-2, apoptosis, P53 and HER-2/neu in breast cancer: a short-term follow-up.
el-Ahmady O; el-Salahy E; Mahmoud M; Wahab MA; Eissa S; Khalifa A
Anticancer Res; 2002; 22(4):2493-9. PubMed ID: 12174951
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of immunohistochemical c-erbB-2 proto-oncogene expression and nuclear DNA content in human breast cancer.
Schimmelpenning H; Eriksson ET; Falkmer UG; Rutqvist LE; Johansson H; Fallenius A; Auer GU
Eur J Surg Oncol; 1992 Dec; 18(6):530-7. PubMed ID: 1362164
[TBL] [Abstract][Full Text] [Related]
16. C-erbB-2 and PCNA as prognostic indicators of long-term survival in breast cancer.
Kato T; Kameoka S; Kimura T; Nishikawa T; Kobayashi M
Anticancer Res; 2002; 22(2B):1097-103. PubMed ID: 12168907
[TBL] [Abstract][Full Text] [Related]
17. Chromosome 11q13, c-erbB-2, and c-myc amplification in invasive breast carcinoma: clinicopathologic correlations.
Gaffey MJ; Frierson HF; Williams ME
Mod Pathol; 1993 Nov; 6(6):654-9. PubMed ID: 7905628
[TBL] [Abstract][Full Text] [Related]
18. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
19. c-erbB-2 amplification in node-negative human breast cancer.
Ro JS; el-Naggar A; Ro JY; Blick M; Frye D; Fraschini G; Fritsche H; Hortobagyi G
Cancer Res; 1989 Dec; 49(24 Pt 1):6941-4. PubMed ID: 2573424
[TBL] [Abstract][Full Text] [Related]
20. Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells?
Tang RP; Kacinski B; Validire P; Beuvon F; Sastre X; Benoit P; dela Rochefordière A; Mosseri V; Pouillart P; Scholl S
J Cell Biochem; 1990 Nov; 44(3):189-98. PubMed ID: 1980125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
